| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3732 |
| Trial ID | NCT06223646 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KQ-2003 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple Myeloma |
| Year | 2024 |
| Country | China |
| Company sponsor | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. |
| Other ID(s) | KQ-2003-AC101 |
| Cohort 1 | |||||||||||
|
|||||||||||